Medicus Pharma wins FDA backing for optimized Phase 2 Teverelix study in acute urinary retention

Medicus Pharma Ltd

Medicus Pharma Ltd

MDCX

0.00
  • Medicus received FDA written feedback backing an optimized Phase 2 Teverelix study in acute urinary retention; FDA response dated July 8, 2026.
  • Protocol redesign cuts planned enrollment to about 126 patients from about 390, aiming to generate an earlier pharmacodynamic signal.
  • ANT-2111-02 is randomized, double-blind, placebo-controlled; tests long-acting GnRH antagonist Teverelix DP via intramuscular and subcutaneous regimens.
  • Primary endpoint targets reduction in total prostate volume; study also tracks recurrent acute urinary retention plus urinary function measures.
  • Central IRB Advarra cleared the protocol with modifications on June 18, 2026, supporting site activation and study start-up work.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160730PRIMZONEFULLFEED9763293) on July 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.